2023
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer
Coman M, Pusztai L, Hooley R, Andreveja L, Kim L, Joshi N, Bersenev A, Krause D, Park T. Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer. Journal Of Immunotherapy 2023, 47: 49-53. PMID: 37991241, DOI: 10.1097/cji.0000000000000495.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCore needle biopsyTriple-negative breast cancerNeedle biopsyBreast cancerEx vivoT-cell receptor clonalityUltrasound-guided core needle biopsyTriple negative breast cancer tumorsMorbidity of surgeryAdoptive cell therapyBreast cancer tumorsTIL generationAdoptive transferTIL culturesMultiple lesionsCytokine secretionMetastatic cancerSame patientTumor tissueCell therapyPatientsCancer tumorsCancerSurgery
2017
Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2008
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. British Journal Of Surgery 2008, 95: 433-437. PMID: 18161887, DOI: 10.1002/bjs.6044.Peer-Reviewed Original ResearchConceptsResidual tumour cellularityNeoadjuvant chemotherapyBreast-conserving surgeryResidual cellularityBreast cancerTumor cellularityIntraoperative marginsInitial breast-conserving surgeryResidual invasive breast cancerInvasive breast cancerPrimary tumor areaInvasive lobular carcinomaFalse-negative marginsCent of specimensInvasive tumor cellsLobular carcinomaMargin rateChemotherapyPatientsPathology slidesCellularityTumor areaSurgeryTumor cellsCancer
2006
The new staging classification: is it useful for clinicians? S Eva Singletary
Pusztai L. The new staging classification: is it useful for clinicians? S Eva Singletary. 2006, 79-92. DOI: 10.1201/b13912-6.Peer-Reviewed Original Research